|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
|
28668888 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Particularly, VEGF mRNA and protein expression and release from glioblastoma cells were also inhibited by TRAIL.
|
16622457 |
2006 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although no effective treatment option is available for recurrent glioblastomas (GBMs), a subset of patients evidently derived clinical benefit from bevacizumab, a monoclonal antibody against vascular endothelial growth factor.
|
29573206 |
2018 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
VEGF expression was significantly higher in older glioblastoma patients (aged > or =55 years).
|
19349600 |
2009 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A strong positive correlation between the mRNA expression levels of HIF-2α, CA9, VEGF, GLUT-1 and OPN suggests a specific hypoxia-associated profile of mRNA expression in glioblastoma multiforme.
|
25963717 |
2015 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of FAT1, EMT (Snail/LOX/Vimentin/N-cad), stemness (SOX2/OCT4/Nestin/REST) and hypoxia markers (HIF-1α/VEGF/PGK1/CA9) was upregulated in ≥39% of GBM tumors (n = 31) with significant positive correlation (p ≤ 0.05) of the expression of FAT1 with LOX/Vimentin/SOX2/HIF-1α/PGK1/VEGF/CA9.
|
28994107 |
2018 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We compared these results with the expression of vascular endothelial growth factor (VEGF), the most potent angiogenic factor in glioblastomas.
|
12445161 |
2002 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
|
27942839 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioblastoma cancer stem-like cells (GCSCs) promote themselves proliferation by secreting the vascular endothelial growth factor A (VEGF<sub>A</sub>) in an autocrine manner, positively regulated by phosphodiesterase IV (PDE4).
|
28202289 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the interplay between metalloproteinases and VEGF previously described in experimental tumours may also be operative in human GBMs.
|
12918061 |
2003 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we isolated a small proportion of CD133+ GSCs from the human glioblastoma cell line U87 and found that these GSCs possessed multipotent differentiation potential and released high levels of VEGF as compared with CD133(-) tumour cells.
|
18523971 |
2008 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment.
|
31040671 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma (GBM).
|
26762204 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reproducible profiles emerged, in which multiple therapeutic targets significant to glioblastoma [matrix metalloproteinases, AKT1 (v-akt murine thymoma viral oncogene homolog 1), epidermal growth factor receptor, vascular endothelial growth factor] showed significant differences in regional expression that may affect treatment response.
|
17122647 |
2006 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma.
|
31723000 |
2020 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The highly vascular malignant brain tumor glioblastoma (GBM) appears to be an ideal target for anti-angiogenic therapy; however, clinical trials to date suggest the VEGF antibody bevacizumab affects only progression-free survival.
|
30680510 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we employed a vector-encoded VEGF siRNA to impair VEGF secretion from U87 human glioblastoma cells.
|
16340308 |
2006 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-210-3p levels were found to be high in GBM patient samples and showed good correlation with the known hypoxia markers CA9 and VEGF.
|
25129238 |
2014 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.
|
25488073 |
2015 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bevacizumab (Bev), a humanized anti-VEGF antibody, is associated with the improvement of progression-free survival and performance status in patients with glioblastoma.
|
28386777 |
2017 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether stem cell marker expression [CD133, CD34, and vascular endothelial growth factor (VEGF)] and IDH1 mutation correlate with clinical factors and prognosis in glioblastoma.
|
24129546 |
2013 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expressions of VEGF mRNA in cultured glioblastomas cells were upregulated by hypoxia, but the sensitivity of the cells to hypoxia was reduced as compared with normal rat astrocytes.
|
11303624 |
2000 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) mRNA levels are increased in GBM and moderate in PA. Immunohistochemical study showed that cytoplasmic AM, VEGF and HIF-1α nuclear immunoreactivity were recorded in GBM located near large necrotic areas whereas they were not expressed by PA tumour cells.
|
21458987 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We show that VEGF pathway blockade resulted in tumor growth retardation and inhibition of tumor vasculature in preclinical models of pediatric glioblastoma and breast cancer brain metastases, suggesting that multiparametric MRI can provide a powerful adjunct to accelerate the development of antiangiogenic therapies for use in these patient populations.
|
28780387 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Studies of glioblastoma angiogenesis have revealed that expression of the vascular endothelial growth factor (VEGF) is up-regulated in these tumors.
|
9592205 |
1998 |